A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
Makoto Endo(Kyushu University), Toshifumi Ozaki(Okayama University), Akihito Nagano(Gifu University), Kazuhiro Tanaka(Oita University), Satoshi Tsukushi(Aichi Cancer Center), Haruhiko Fukuda(National Cancer Center Hospital East), Hiroyuki Kawashima(Niigata University Medical and Dental Hospital), Shintaro Iwata(National Cancer Centre Japan), Munenori Watanuki(Tohoku University Hospital), Hiroaki Hiraga, Hiroyuki Tsuchiya(Yokohama Sakae Kyosai Hospital), Tsukasa Yonemoto, T. Akiyama, Tomoko Kataoka(Japan Clinical Cancer Research Organization), Robert Nakayama(Keio University), Ryunosuke Machida(Japan Clinical Cancer Research Organization), Yoshihiro Matsumoto(Jikei University Kashiwa hospital), Satoshi Takenaka(Osaka International Cancer Institute), Keisuke Ae(The Cancer Institute Hospital), Hirohisa Katagiri(Shizuoka Cancer Center)
Cited by 0
Related Papers
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201)
|Journal of Thoracic Oncology|2011|656
Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201
|Journal of Thoracic and Cardiovascular Surgery|2013|348
Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group
|Journal of Clinical Oncology|2003|344